New Orleans, LAWith Xarelto lawsuits now consolidated in a multidistrict litigation, plaintiffs can look forward to 2015 and decisions regarding the start of bellwether trials in the litigation. Lawsuits filed against the makers of Xarelto allege the companies failed to properly warn patients about the risk of Xarelto bleeding complications, including that Xarelto does not have an antidote.
The decision to consolidate Xarelto lawsuits for pretrial proceedings was announced in December 2014, and affects approximately two dozen lawsuits already filed. However, the announcement of a multidistrict litigation could encourage other patients to come forward, so the number of consolidated lawsuits could grow.
The panel noted that as of the time of consolidation there were 21 lawsuits pending in 10 districts, with the plaintiffs disagreeing about where the lawsuits should be consolidated. The defendants argued against centralization, noting that there are individualized facts for each lawsuit, including the patient’s medical history and dosage; that informal coordination would take care of overlapping discovery; that attorney advertising suggested the cases lack merit; and that an MDL would encourage a flood of copycat complaints.
Judges on the panel wrote in the ruling that although there were individualized facts concerning each lawsuit, there were several important common issues, including the adequacy of Xarelto’s warning label, the results of clinical studies and the alleged need for blood monitoring.
“Almost all personal injury litigation involves questions of causation that are plaintiff-specific,” the panel wrote. “Those differences are not an impediment to centralization where common questions of fact predominate.”
The panel further ruled that “considerable growth in the litigation over the past few months” made informal coordination of discovery impractical and rejected the argument that attorney advertising suggested the cases lacked merit. Finally they wrote that transferring all the cases to one judge would be no worse than having several courts address meritless claims and may even be better able to deal with such claims quickly.
As such, the panel ruled that centralization of the lawsuits for pretrial proceedings was the best option, and transferred the lawsuits to the Eastern District of Louisiana before Judge Eldon E. Fallon. An initial status conference on the litigation is reportedly scheduled for later in January 2015.
The lawsuit is Xarelto Products Liability Litigation, MDL No. 2592, U.S. Judicial Panel on Multidistrict Litigation.
If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your Xarelto claim at no cost or obligation.